EI
FOLD

EAM Investors’s Amicus Therapeutics FOLD Stock Holding History

EAM Investors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-168,399
Closed -$1.76M – 292
2022
Q3 		$1.76M Sell
168,399
-45,634
-21% -$508K 0.38% 107
2022
Q2 		$2.3M Buy
+214,033
New +$1.76M 0.56% 57
2021
Q1 		– Sell
-87,882
Closed -$2.03M – 375
2020
Q4 		$2.03M Buy
+87,882
New +$1.8M 0.33% 114
2015
Q4 		– Sell
-310,394
Closed -$4.34M – 327
2015
Q3 		$4.34M Sell
310,394
-204,076
-40% -$3.2M 0.69% 14
2015
Q2 		$7.28M Sell
514,470
-111,224
-18% -$1.34M 0.85% 4
2015
Q1 		$6.81M Sell
625,694
-164,146
-21% -$1.45M 0.79% 2
2014
Q4 		$6.57M Buy
789,840
+177,641
+29% +$1.22M 0.92% 5
2014
Q3 		$3.64M Buy
+612,199
New +$3.21M 0.74% 7

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM Investors's FOLD Position: Q4 2022 in Review

EAM Investors sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 168,399 shares — an estimated $1.76M sold.

EAM Investors first reported a position in FOLD in Q3 2014 and held it in 8 quarters. The position peaked at $7.28M in Q2 2015. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • EAM Investors reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 168,399 Amicus Therapeutics shares in Q4 2022, an estimated $1.76M.
  • EAM Investors first reported a position in Amicus Therapeutics in Q3 2014 and held it in 8 quarters.
  • EAM Investors's Amicus Therapeutics position peaked at $7.28M in Q2 2015.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.